pritelivir
Small moleculeexperimental
Pritelivir is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020. — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01047540)
Timeline
Indications
Mechanism of action
Herpes simplex virus (type 1 / strain F) inhibitor
- Helicase/primaseINHIBITOR
Helicase/primase inhibitor
- Helicase/primaseINHIBITOR
Helicase/primase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O- Mol. weight
- 402.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPritelivir ↗
- ChEMBLCHEMBL4069597 ↗
Also known as
- aic316
- aic316
- aic316
- bay 57-1293
- n-(5-(aminiosulfonyl)-4-methyl-1,3-thiazol-2-yl)-n-methyl-2-(4-(2-pyridinyl)phenyl)acetamide
- pritelivir
- pritelivir
- pritelivir
- pritelivir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05513625 | Phase 1 | Jul 13, 2020 | AiCuris Anti-infective Cures GmbH |
| NCT03073967 | Phase 2 | May 8, 2017 | AiCuris Anti-infective Cures GmbH, Medpace, Inc. |
| NCT02871492 | Phase 2 | Nov 29, 2016 | AiCuris Anti-infective Cures GmbH, Novella Clinical |
| NCT01658826 | Phase 2 | Oct 1, 2012 | AiCuris Anti-infective Cures GmbH, Medpace, Inc. |
| NCT01047540 | Phase 2 | Mar 1, 2010 | AiCuris Anti-infective Cures GmbH, FHI 360 |
| NCT05844436 | N/A | — | AiCuris Anti-infective Cures GmbH, myTomorrows |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AiCuris Anti-infective Cures GmbH | For profit | 6 | 6 | 3 | 2010 |
| Medpace, Inc. | For profit | 2 | 0 | 1 | 2012 |
| FHI 360 | Academic/Hospital | 1 | 0 | 1 | 2010 |
| myTomorrows | Academic/Hospital | 1 | 0 | 1 | — |
| Novella Clinical | For profit | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1